Patents by Inventor Robert J. Lutz
Robert J. Lutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368270Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.Type: ApplicationFiled: April 12, 2024Publication date: November 7, 2024Inventors: Robert J. LUTZ, Jose PONTE
-
Publication number: 20210155688Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.Type: ApplicationFiled: January 15, 2021Publication date: May 27, 2021Inventors: Robert J. LUTZ, Jose PONTE
-
Publication number: 20180362646Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: ApplicationFiled: May 14, 2018Publication date: December 20, 2018Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Patent number: 10000566Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: May 13, 2016Date of Patent: June 19, 2018Assignee: IMMUNOGEN, INC.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20170080102Abstract: The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.Type: ApplicationFiled: May 19, 2015Publication date: March 23, 2017Inventors: Kathleen R. Whiteman, Paul Noordhuis, Yelena Kovtun, Robert J. Lutz, Gerrit Jan Schuurhuis, Russell Marlin Walker
-
Publication number: 20160362490Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: ApplicationFiled: May 13, 2016Publication date: December 15, 2016Applicant: IMMUNOGEN INC.Inventors: Mary G. HOFFEE, Daniel TAVARES, Robert J. LUTZ
-
Patent number: 9359442Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: April 10, 2014Date of Patent: June 7, 2016Assignee: IMMUNOGEN INC.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20150343077Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.Type: ApplicationFiled: May 12, 2015Publication date: December 3, 2015Inventors: Jutta DECKERT, Robert J. LUTZ, Joanne Elizabeth Sarah SCHINDLER, Rodrigo Ricardo RUIZ SOTO
-
Publication number: 20150297744Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.Type: ApplicationFiled: March 27, 2015Publication date: October 22, 2015Applicant: ImmunoGen, Inc.Inventors: Robert J. LUTZ, Jose Ponte, Yinghui Zhou
-
Publication number: 20150132323Abstract: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.Type: ApplicationFiled: October 8, 2014Publication date: May 14, 2015Inventors: ROBERT J. LUTZ, JOSE PONTE
-
Publication number: 20140248267Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: ApplicationFiled: April 10, 2014Publication date: September 4, 2014Applicant: IMMUNOGEN INC.Inventors: Mary G. HOFFEE, Daniel TAVARES, Robert J. LUTZ
-
Patent number: 8747851Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: November 19, 2012Date of Patent: June 10, 2014Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20140093523Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicants: Immunogen, Inc., Janssen Biotech, Inc.Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
-
Patent number: 8603483Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.Type: GrantFiled: November 30, 2005Date of Patent: December 10, 2013Assignees: Janssen Biotech, Inc., Immunogen, Inc.Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
-
Patent number: 8563700Abstract: The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent(s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone.Type: GrantFiled: June 16, 2009Date of Patent: October 22, 2013Assignee: ImmunoGen, Inc.Inventors: Robert J. Lutz, Kathleen R. Whiteman
-
Patent number: 8409166Abstract: Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity.Type: GrantFiled: April 26, 2011Date of Patent: April 2, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Stephen M. Wiener, Robert F. Hoyt, Jr., John R. Deleonardis, Randall R. Clevenger, Robert J. Lutz, Douglas V. Christini, Brian Safer
-
Patent number: 8388960Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.Type: GrantFiled: September 9, 2011Date of Patent: March 5, 2013Assignee: Immunogen Inc.Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson, Wayne C. Widdison
-
Patent number: 8337855Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: February 2, 2011Date of Patent: December 25, 2012Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20120282282Abstract: The invention relates to charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of using the same to reduce ocular toxicity associated with administration of antibody drug conjugates.Type: ApplicationFiled: April 4, 2012Publication date: November 8, 2012Applicant: ImmunoGen, Inc.Inventors: Robert J. Lutz, Ravi V.J. Chari
-
Patent number: 8137669Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.Type: GrantFiled: August 5, 2008Date of Patent: March 20, 2012Assignee: Immunogen, Inc.Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson